Literature DB >> 15917414

Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types.

J Malta-Vacas1, C Aires, P Costa, A R Conde, S Ramos, A P Martins, C Monteiro, M Brito.   

Abstract

BACKGROUND: There are now several lines of evidence to suggest that protein synthesis and translation factors are involved in the regulation of cell proliferation and cancer development. AIMS: To investigate gene expression patterns of eukaryotic releasing factor 3 (eRF3) in gastric cancer.
METHODS: RNA was prepared from 25 gastric tumour biopsies and adjacent non-neoplastic mucosa. Real time TaqMan reverse transcription polymerase chain reaction (RT-PCR) was performed to measure the relative gene expression levels. DNA was isolated from tumour and normal tissues and gene dosage was determined by a quantitative real time PCR using SYBR Green dye.
RESULTS: Different histological types of gastric tumours were analysed and nine of the 25 tumours revealed eRF3/GSPT1 overexpression; moreover, eight of the 12 intestinal type carcinomas analysed overexpressed the gene, whereas eRF3/GSPT1 was overexpressed in only one of the 10 diffuse type carcinomas (Kruskal-Wallis Test; p < 0.05). No correlation was found between ploidy and transcript expression levels of eRF3/GSPT1. Overexpression of eRF3/GSPT1 was not associated with increased translation rates because the upregulation of eRF3/GSPT1 did not correlate with increased eRF1 levels.
CONCLUSIONS: Overexpression of eRF3/GSPT1 in intestinal type gastric tumours may lead to an increase in the translation efficiency of specific oncogenic transcripts. Alternatively, eRF3/GSPT1 may be involved in tumorigenesis as a result of its non-translational roles, namely (dis)regulating the cell cycle, apoptosis, or transcription.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917414      PMCID: PMC1770693          DOI: 10.1136/jcp.2004.021774

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  46 in total

1.  Assignment of the human peptide chain release factor 3 (GSPT2) to Xp11.23-->p11.21 and of the distal marker DXS1039 by radiation hybrid mapping.

Authors:  L L Hansen; C G Jakobsen; J Justesen
Journal:  Cytogenet Cell Genet       Date:  1999

Review 2.  Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation.

Authors:  M Caraglia; A Budillon; G Vitale; G Lupoli; P Tagliaferri; A Abbruzzese
Journal:  Eur J Biochem       Date:  2000-07

3.  MUC1 gene polymorphism in the gastric carcinogenesis pathway.

Authors:  F Silva; F Carvalho; A Peixoto; M Seixas; R Almeida; F Carneiro; P Mesquita; C Figueiredo; C Nogueira; D M Swallow; A Amorim; L David
Journal:  Eur J Hum Genet       Date:  2001-07       Impact factor: 4.246

4.  Targets of gene amplification and overexpression at 17q in gastric cancer.

Authors:  Asta Varis; Maija Wolf; Outi Monni; Marja-Leena Vakkari; Arto Kokkola; Chris Moskaluk; Henry Frierson; Steven M Powell; Sakari Knuutila; Anne Kallioniemi; Wa'el El-Rifai
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

Review 5.  Gastric adenocarcinoma: pathomorphology and molecular pathology.

Authors:  M Werner; K F Becker; G Keller; H Höfler
Journal:  J Cancer Res Clin Oncol       Date:  2001-04       Impact factor: 4.553

6.  Association of p53 genomic instability with the glutathione S-transferase null genotype in gastric cancer in the Portuguese population.

Authors:  A R Conde; G Martins; C Saraiva; J Rueff; C Monteiro
Journal:  Mol Pathol       Date:  1999-06

7.  Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations.

Authors:  D G Huntsman; F Carneiro; F R Lewis; P M MacLeod; A Hayashi; K G Monaghan; R Maung; R Seruca; C E Jackson; C Caldas
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

8.  Recessive mutations in SUP35 and SUP45 genes coding for translation release factors affect chromosome stability in Saccharomyces cerevisiae.

Authors:  A S Borchsenius; A A Tchourikova; S G Inge-Vechtomov
Journal:  Curr Genet       Date:  2000-05       Impact factor: 3.886

9.  Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas.

Authors:  M Rothe; Y Ko; P Albers; N Wernert
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

10.  The expression of poly(A)-binding protein gene is translationally regulated in a growth-dependent fashion through a 5'-terminal oligopyrimidine tract motif.

Authors:  E Hornstein; A Git; I Braunstein; D Avni; O Meyuhas
Journal:  J Biol Chem       Date:  1999-01-15       Impact factor: 5.157

View more
  12 in total

Review 1.  The biological and therapeutic relevance of mRNA translation in cancer.

Authors:  Sarah P Blagden; Anne E Willis
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

2.  Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway.

Authors:  Céline Chauvin; Samia Salhi; Olivier Jean-Jean
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

3.  EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts.

Authors:  Jing Fang; Madhu Menon; William Kapelle; Olga Bogacheva; Oleg Bogachev; Estelle Houde; Sarah Browne; Pradeep Sathyanarayana; Don M Wojchowski
Journal:  Blood       Date:  2007-06-04       Impact factor: 22.113

4.  Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner.

Authors:  Sajitha Nair; Namrata Bora-Singhal; Deepak Perumal; Srikumar Chellappan
Journal:  Mol Cancer       Date:  2014-07-16       Impact factor: 27.401

5.  Eukaryotic translational termination efficiency is influenced by the 3' nucleotides within the ribosomal mRNA channel.

Authors:  Andrew G Cridge; Caillan Crowe-McAuliffe; Suneeth F Mathew; Warren P Tate
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

6.  Role of GSPT1 and GSPT2 polymorphisms in different outcomes upon Hepatitis B virus infection and prognosis to lamivudine therapy.

Authors:  Wenxuan Liu; Ning Ma; Xia Gao; Wencong Liu; Jinhai Jia; Longmei Tang; Man Li; Lei Yang; Tao Li; Lina Yan; Xiaolin Zhang; Fengxue Yu
Journal:  Biosci Rep       Date:  2019-03-28       Impact factor: 3.840

7.  BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers.

Authors:  Y Hirata; N Ogasawara; M Sasaki; T Mizushima; T Shimura; T Mizoshita; Y Mori; E Kubota; T Wada; S Tanida; H Kataoka; T Kamiya; S Higashiyama; T Joh
Journal:  Br J Cancer       Date:  2009-03-31       Impact factor: 7.640

8.  eRF3b, a biomarker for hepatocellular carcinoma, influences cell cycle and phosphoralation status of 4E-BP1.

Authors:  Man Li; Jian Wang; Lei Yang; Ping Gao; Qing-Bao Tian; Dian-Wu Liu
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

9.  Glucocorticoid counteracts cellular mechanoresponses by LINC01569-dependent glucocorticoid receptor-mediated mRNA decay.

Authors:  Huayu Zhu; Jun Li; Yize Li; Zhao Zheng; Hao Guan; Hongtao Wang; Ke Tao; Jiaqi Liu; Yunchuan Wang; Wanfu Zhang; Chao Li; Jie Li; Lintao Jia; Wendong Bai; Dahai Hu
Journal:  Sci Adv       Date:  2021-02-24       Impact factor: 14.136

10.  Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.

Authors:  Gisele Nishiguchi; Fatemeh Keramatnia; Jaeki Min; Yunchao Chang; Barbara Jonchere; Sourav Das; Marisa Actis; Jeanine Price; Divyabharathi Chepyala; Brandon Young; Kevin McGowan; P Jake Slavish; Anand Mayasundari; Jamie A Jarusiewicz; Lei Yang; Yong Li; Xiang Fu; Shalandus H Garrett; James B Papizan; Kiran Kodali; Junmin Peng; Shondra M Pruett Miller; Martine F Roussel; Charles Mullighan; Marcus Fischer; Zoran Rankovic
Journal:  J Med Chem       Date:  2021-05-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.